Diseases

Lilly wins EU backing for version of insulin drug

June 27, 2014
Bloomberg News
Lantus, which garnered $7.8 billion in sales for Paris-based Sanofi in 2013, loses patent protection in Europe in May next year.
More

Insurance changes put state's autism industry on edge

June 14, 2014
J.K. Wall
Indiana's autism therapists say their prospects are cloudy after the state’s largest health insurer, Anthem Blue Cross and Blue Shield, cut payments 40 percent and took a harder line on paying for therapy for school-age children.
More

Endocyte shares plunge 60 percent after drug trial is stopped

May 2, 2014
 Bloomberg News and IBJ Staff
Endocyte Inc.'s stock fell more than 60 percent in early trading Friday after the drug it’s developing with Merck & Co.’s backing failed to help patients in a trial for ovarian cancer.
More

Cancer treatment makes Endocyte premium takeover target

March 28, 2014
Bloomberg News
Now that Indiana-based Endocyte Inc.’s experimental cancer treatment is proving successful, the company may command a takeover bid at one of the industry’s highest premiums on record.
More

Endocyte stock doubles after key approval in Europe

March 21, 2014
Bloomberg News, J.K. Wall
The stock price of Endocyte Inc. skyrocketed by as much as 130 percent Friday morning after the drug company got a thumbs up in Europe to market its first drug and received a new round of favorable clinical trial results.
More

Lilly diabetes drug wins backing from EU regulator

March 21, 2014
Bloomberg News
Indianapolis-based Lilly is expected to garner $518 million in annual sales from Jardiance by 2019, according to the average of five analyst estimates compiled by Bloomberg.
More

Lilly diabetes drug rejected by FDA over manufacturing issue

March 5, 2014
Bloomberg News
The Lilly-Boehringer drug empagliflozin is projected to reach sales of $295 million for Lilly in 2019, but it won't be able to sell it until issues are resolved at a German plant.
More

Indiana one of many states aiming to limit tanning

March 2, 2014
Associated Press
Lawmakers' efforts to crack down on the use of Indiana tanning beds this year are part of a national push to limit young people's exposure to risks that include skin cancer.
More

Lilly diabetes drug matches competitors' effectiveness

February 25, 2014
 IBJ Staff and Bloomberg News
The Indianapolis drugmaker said dulaglutide performed as well as Victoza, a best-selling drug for Type 2 diabetics made by Denmark-based Novo Nordisk. Analysts think dulaglutide could reach annual sales of $1.5 billion.
More

U.S. venture gathers drugmakers to take on major diseases

February 4, 2014
Bloomberg News
Eli Lilly and Co., Pfizer Inc. and eight other large drugmakers will partner with the U.S. government in a $230 million effort to identify new approaches to treat Alzheimer’s, diabetes, lupus and arthritis.
More

Three groups puzzled by woman's $7 million bequest

January 8, 2014
Associated Press
The organizations which include Indianapolis-based Hoosier Oncology Group have no idea why an Evansville teacher chose them as beneficiaries.
More

Pfizer, Teva reach deal to allow generic Viagra

December 18, 2013
Bloomberg News
Fifteen years after Pfizer Inc.’s Viagra changed the sexual equation for older men, the blockbuster impotence drug is set to become available in a less expensive generic form as early as 2017.
More

Lilly foe still testing Alzheimer's theory where others failed

December 12, 2013
Bloomberg News
Since 1998, there have been more than 100 attempts to develop an Alzheimer’s treatment, and all have failed. Such a product may generate as much as $5 billion annually for Merck, according to analysts
More

Lilly to spend another $700M in growing market for diabetes products

November 14, 2013
 IBJ Staff, Bloomberg News
The move includes a $45 million investment for Lilly's operations in Indianapolis, on top of $400 million in investments the company announced over the past two years.
More

Lilly, other drugmakers itching to find new psoriasis treatment

October 4, 2013
Bloomberg News
Psoriasis is linked to higher rates of heart disease and diabetes, and a third of patients also develop a form of arthritis. About 125 million people worldwide have the skin condition, including 7.5 million Americans.
More

Lilly bets quality over quantity will pay off in diabetes battle

September 24, 2013
Bloomberg News
Eli Lilly and Co. is counting on the quality of a diversified product portfolio over boosting its sales forces to grab a bigger slice of the $22 billion U.S. diabetes market, a difference in strategy to some of its rivals.
More

Anthem rolls out new bonus system for docsRestricted Content

September 21, 2013
J.K. Wall
The Indianapolis-based health insurer expects to pay, on average, $3.50 per month for every patient enrolled in one of Anthem’s commercial health plans.
More

Alzheimer’s targeted in $45M government study grant

September 18, 2013
Bloomberg News
Part of the funding will go to an existing study of drugs from Eli Lilly and Co. and others to see whether they can ward off the disease in people who inherited genes that predestine them to get Alzheimer's.
More

Lilly lung cancer drug raises patient survival in trial

August 13, 2013
Bloomberg News
If approved, the drug would be a potent boost to Lilly’s product portfolio. It would also mean a critical new therapy for a cancer that’s proven difficult to treat.
More

Roche to cut local jobs after diabetes-care sales plunge

August 5, 2013
J.K. Wall
Roche's diabetes care unit, which employs more than 900 in Indianapolis, suffered a 14-percent decline in revenue during the first half of 2013. Roche has reportedly put the unit up for sale.
More

Lilly drug for Alzheimer's gets limited Medicare coverage

July 8, 2013
Bloomberg News, Associated Press
Lilly officials said they will push ahead with the first-of-a-kind imaging chemical, despite the mostly negative ruling by Medicare officials.
More

Lilly wins patent lawsuit on J&J Alzheimer’s research

June 25, 2013
Bloomberg News
A patent held by J&J’s Janssen Alzheimer Immunotherapy Research & Development unit isn’t valid, Judge Richard Arnold said in a ruling in London Tuesday.
More

Lilly’s experimental diabetes drug helps patients lose weight

June 24, 2013
Bloomberg News
Lilly’s drug, if approved, may be a significant competitor to Novo Nordisk A/S’s Victoza, which generated $1.64 billion in 2012.
More

Lilly halts trial of experimental Alzheimers drug

June 14, 2013
The trial ended after participants showed abnormal liver biochemistry, the Indianapolis-based drugmaker said Thursday in a statement.
More

New law lets pharmacists provide pneumonia, HPV vaccines

June 13, 2013
 The Statehouse File
Starting July 1, pharmacists will be able to offer a much wider variety of immunizations to customers, in an effort from lawmakers to make health care more accessible.
More
Page  1 2 3 4 5 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. I am a Lyft driver who is a licensed CDL professional driver. ALL Lyft drivers take pride in providing quality service to the Indianapolis and surrounding areas, and we take the safety of our passengers and the public seriously.(passengers are required to put seat belts on when they get in our cars) We do go through background checks, driving records are checked as are the personal cars we drive, (these are OUR private cars we use) Unlike taxi cabs and their drivers Lyft (and yes Uber) provide passengers with a clean car inside and out, a friendly and courteous driver, and who is dressed appropriately and is groomed appropriately. I go so far as to offer mints, candy and/or small bottle of water to the my customers. It's a mutual respect between driver and passenger. With Best Regards

  2. to be the big fish in the little pond of IRL midwest racin' when yer up against Racin' Gardner

  3. In the first sentance "As a resident of one of these new Carmel Apartments the issue the local governments need to discuss are build quality & price." need a way to edit

  4. As a resident of one of these new Carmel Apartments the issue the local governments need to discuss is build quality & price. First none of these places is worth $1100 for a one bedroom. Downtown Carmel or Keystone at the Crossing in Indy. It doesn't matter. All require you to get in your car to get just about anywhere you need to go. I'm in one of the Carmel apartments now where after just 2.5 short years one of the kitchen cabinet doors is crooked and lawn and property maintenance seems to be lacking my old Indianapolis apartment which cost $300 less. This is one of the new star apartments. As they keep building throughout the area "deals" will start popping up creating shoppers. If your property is falling apart after year 3 what will it look like after year 5 or 10??? Why would one stay here if they could move to a new Broad Ripple in 2 to 3 years or another part of the Far Northside?? The complexes aren't going to let the "poor" move in without local permission so that's not that problem, but it the occupancy rate drops suddenly because the "Young" people moved back to Indy then look out.

  5. Why are you so concerned about Ace hardware? I don't understand why anyone goes there! Every time ive gone in the past, they don't have what I need and I end up going to the big box stores. I understand the service aspect and that they try to be helpful but if they are going to survive I think they might need to carry more specialty parts.

ADVERTISEMENT